上海醫藥(601607.SH):擬出資9000萬元參設生物醫藥產業專項基金
格隆匯7月23日丨上海醫藥(601607.SH)公佈,公司擬作為有限合夥人之一參與設立上海上實生物醫藥創新轉化私募投資基金合夥企業(有限合夥)(“標的基金”),出資金額為人民幣(下同)9000萬元。
標的基金是由上海實業(集團)有限公司(“上實集團”)發起設立的生物醫藥產業專項基金。標的基金立足上海、聯動長三角和粵港澳大灣區、面向全球為定位,對附有創新屬性和成果轉化價值的項目提供系統性投資和轉化支持,重點投向生物醫藥領域,打造一個國內領先的生物醫藥領域創新轉化平台。
通過參與標的基金,公司在獲取合理投資收益的同時,還將在未來與標的基金形成多方面的戰略協同,實現生物醫藥領先創新科技及應用更廣泛的佈局,醫藥及醫療產業更深入的協同及生態圈建設,以更靈活且市場化的資本運作方式,進一步助推上海醫藥實現其未來戰略及發展目標。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.